Epigral to host Bellwether Capital for plant visit in Gujarat

scanx
Reviewed by
Naman SScanX News Team
Key Highlights
  • Epigral Limited hosts Bellwether Capital for a plant visit
  • Event scheduled for September 3, 2026 in Dahej, Gujarat
  • Disclosure made under SEBI LODR Regulation 30
  • No unpublished price-sensitive information to be shared
powered bylight_fuzz_icon
49728468

*this image is generated using AI for illustrative purposes only.

Epigral Limited has scheduled an investor and analyst plant visit for September 3, 2026. The company will host representatives from Bellwether Capital at its manufacturing facility in Dahej, Gujarat.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Epigral informed the National Stock Exchange of India Limited and BSE Limited on August 31, 2026, regarding the upcoming engagement.

Visit Details

The plant visit is planned for Thursday, September 3, 2026. The location is the Dahej unit in Gujarat. The mode of interaction is an in-person plant visit.

Detail Information
Investor/Analyst Bellwether Capital
Date September 3, 2026
Location Dahej, Gujarat
Mode Plant Visit

Regulatory Disclosures

Epigral stated that the schedule is subject to change due to exigencies on the part of the analyst, investor, or the company. The firm emphasized that no unpublished price-sensitive information will be shared or discussed during the visit.

Gaurang Trivedi, Company Secretary and Compliance Officer, signed the intimation filed with the exchanges.

Historical Stock Returns for Epigral

1 Day5 Days1 Month6 Months1 Year5 Years
-2.39%+6.87%+2.80%+34.93%-33.83%0.0%

How might the insights shared with Bellwether Capital regarding Epigral's Dahej facility impact short-term stock valuation and institutional interest?

What specific capacity expansion or efficiency improvements at the Gujarat plant could be highlighted to justify future growth projections?

Will this engagement signal a broader strategy by Epigral to attract foreign or domestic institutional investors beyond its current shareholder base?

Epigral schedules one-on-one meeting with Incred Research on August 20

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights

Epigral Limited has scheduled a one-on-one meeting with Incred Research Services Pvt. Ltd. on August 20, 2026, in Ahmedabad, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that no unpublished price sensitive information will be shared during the meeting. Relevant presentations have been made available on the company's website ahead of the interaction.

powered bylight_fuzz_icon
48606259

*this image is generated using AI for illustrative purposes only.

Epigral Limited has notified the stock exchanges of a one-on-one meeting with Incred Research Services Pvt. Ltd., scheduled for August 20, 2026, in Ahmedabad. The intimation was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has confirmed that no unpublished price sensitive information will be shared or discussed in the meeting.

Meeting details

The key details of the scheduled interaction are as follows:

Parameter: Details
Investor/Analyst: Incred Research Services Pvt. Ltd.
Date: August 20, 2026
Mode: One-on-One Meeting
Location: Ahmedabad

Presentation availability

Epigral noted that the latest Earnings Presentation and Corporate Presentation that may be discussed during the meeting have already been placed on the company's website. The schedule of the meeting is subject to change due to exigencies on the part of institutional investors or the company.

Historical Stock Returns for Epigral

1 Day5 Days1 Month6 Months1 Year5 Years
-2.39%+6.87%+2.80%+34.93%-33.83%0.0%

How might Incred Research's upcoming coverage or rating change following this one-on-one meeting impact Epigral's stock valuation?

What specific operational or financial metrics is Epigral likely to highlight to institutional investors to justify its current market position?

Could this engagement signal Epigral's intent to increase its visibility among domestic institutional investors ahead of any potential fundraising activities?

More News on Epigral

1 Year Returns:-33.83%